Table 2

HFpEF characteristics and medications

Disease related characteristics
 NYHA class II10 (42%)
 NYHA class III10 (42%)
 NYHA class IV4 (17%)
 Six-min walk distance, m402±42
 B-type natriuretic peptide, pg/mL150±26
 Diabetes10 (42%)
 COPD2 (8%)
 CAD6 (25%)
 Hypertension20 (83%)
EchocardiographyValueReference range
 Ejection fraction, %62±1≥55
 LV IVSD, cm1.1±0.10.6–1.1
 LV PWD, cm1.1±0.10.6–0.9
 LV ID diastole, cm4.5±0.23.9–5.3
 LV ID systole, cm3.0±0.12.0–4.0
 Peak E wave, cm/s84±7
 Peak A wave, cm/s96±11
 E/A ratio1.1±0.20.6–1.32
 E′ lateral wall, cm/s7±113–28
 E/E′ ratio13±2≤8
Mitral E-wave deceleration time, ms246±14142–258
 β receptor blocker11 (46%)
 ACEi or ARB15 (63%)
 Loop diuretics22 (92%)
 Aldosterone antagonist16 (67%)
 Statin18 (75%)
 Nitrates5 (21%)
 Calcium channel blockers3 (13%)
  • Data are mean±SEM or % of group.

  • ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HFpEF, heart failure with preserved ejection fraction; LV ID, left ventricle internal diameter; LV IVSD, left ventricle interventricular septum diameter; LV PWD, left ventricle posterior wall diameter; NYHA, New York Heart Association.